Our project "Malaria Vaccine Development and Establishment of its Commercial Manufacturing" selected for the Cyclic Innovation for Clinical Empowerment (CiCLE) by the Japan Agency for Medical Research and Development (AMED) in the first recruitment

At the Japan Venture Awards 2017, held by Organization for Small & Medium Enterprises and Regional Innovation, Japan on February 6, 2017, the President and CEO of Nobelpharma, Mr. Jin Shiomura, has received “the Economy, Trade and Industry Minister Prize”

Marketing authorization for Foscavir^®, antiviral chemothrapeutic agent, transferred to Clinigen KK

Titanium bridge (NPC-17) received orphan designation from MHLW

Received Lisence for Marketing Class 1 Medical Devices

NPC-04 (oxcarbazepine) Approved by PMDA for the Treatment of Partial Epilepsy

Nobelpharma signs license agreement with Danish Serendex Pharmaceuticals A/S for future commercialization of Molgradex^®(inhaled GM-CSF therapy) for Pulmonary Alveolar Proteinosis in Japan